Loading organizations...
Illumina, based in San Diego, California, develops and markets integrated systems for genetic variation analysis and biological function, including DNA sequencing and array-based technologies. These tools facilitate high-throughput sequencing, genotyping, and gene expression analysis for genomics research and applications, serving a global customer base with nearly 10,000 employees across 34 locations. Early investors in the company included firms such as Domain Associates, Warburg Pincus, and CW Group. The publicly traded company (NASDAQ: ILMN) has been a significant player in the genomics sector, powering discoveries in personalized health. Illumina was founded on April 1, 1998, by David Walt, John Stuelpnagel, Anthony Czarnik, Mark Chee, Kevin Gunderson, and Larry Bock. Its business model centers on publicly traded company that sells sequencing instruments, consumables, and services to generate revenue.
Key people at Illumina.
Illumina was founded in 1998 by David R. Walt (Scientific Founder & Board Director).
Illumina was founded in 1998 by David R. Walt (Scientific Founder & Board Director).
Illumina is a global leader in genomics technology, specializing in DNA sequencing and array-based solutions that enable research discovery and personalized health applications. It serves customers across research, clinical, and applied markets, addressing challenges in oncology, genetic and infectious diseases, reproductive health, agriculture, and other emerging fields. Illumina’s products help unlock genomic insights that drive advances in disease understanding, biomarker discovery, and precision medicine. The company has demonstrated steady growth momentum, with Q3 2025 revenue of $1.08 billion and ongoing innovation such as its 5-base solution for multiomic analysis and the launch of BioInsight, a new business focused on data-driven life science breakthroughs[1][2][3][6].
Founded in 1998, Illumina was established to make a difference in human health by unlocking the power of the genome. Its founders brought expertise in genomics and technology innovation, and the company quickly became a pioneer in DNA sequencing technologies. Early traction came from its ability to deliver scalable, cost-effective genomic tools that transformed research and clinical diagnostics. Over more than 25 years, Illumina has evolved by expanding its product portfolio and entering new markets, including personalized cancer care and pharmaceutical partnerships, while maintaining a strong focus on innovation and collaboration[4][2].
Illumina rides the wave of increasing adoption of genomic sequencing and multiomic data analysis in healthcare and life sciences. The timing is critical as precision medicine, cancer genomics, and large-scale population genetics projects gain momentum globally. Market forces such as rising demand for personalized therapies, advances in AI for biological data interpretation, and growing investments in genomics research favor Illumina’s growth. The company influences the broader ecosystem by enabling researchers and clinicians to generate and analyze complex biological data, accelerating discoveries that impact health outcomes and biopharmaceutical innovation[3][6][2].
Looking ahead, Illumina is positioned to expand its leadership by deepening its multiomic capabilities and scaling its data-driven business models through BioInsight. Trends such as AI integration in genomics, expansion of clinical sequencing, and personalized cancer care will shape its trajectory. While competition and pricing pressures remain challenges, Illumina’s strong innovation pipeline and strategic partnerships support sustained growth. Its influence is likely to grow as genomic technologies become increasingly central to healthcare and biological research, reinforcing its mission to improve human health through genome science[5][3][6].
Key people at Illumina.
Illumina has 9 tracked investments across 9 companies. The latest tracked deal is $9.0M Series A in Mantra Bio in January 2023.
